Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis

(2015) Pietro Iaffaldano et al.   BRAIN

Switching from natalizumab to fingolimod

(2015) Ludwig Kappos et al.   NEUROLOGY

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy

(2014) Tatiana Plavina et al.   ANNALS OF NEUROLOGY

Natalizumab: Risk Stratification of Individual Patients with Multiple Sclerosis

(2014) Carmen Tur et al.   CNS DRUGS

We know how to prescribe natalizumab for multiple sclerosis, but do we know how to withdraw it?

(2014) Yara D Fragoso et al.   Expert Review of Neurotherapeutics

A changing treatment landscape for multiple sclerosis: challenges and opportunities

(2014) F. Piehl   JOURNAL OF INTERNAL MEDICINE

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab

(2014) Marinella Clerico et al.   JAMA Neurology

Switching From Natalizumab to Fingolimod in Multiple Sclerosis

(2014) Mikael Cohen et al.   JAMA Neurology

Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients

(2014) Francesca Sangalli et al.   Multiple Sclerosis and Related Disorders

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients

(2014) Tuan Dong-Si et al.   Annals of Clinical and Translational Neurology

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

(2011) Ludwig Kappos et al.   LANCET NEUROLOGY

Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis

(2011) A Scott Nielsen et al.   Multiple Sclerosis Journal

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

(2011) P. W. O'Connor et al.   NEUROLOGY

Natalizumab dosage suspension: Are we helping or hurting?

(2010) Timothy W. West et al.   ANNALS OF NEUROLOGY

Anti-JC virus antibodies: Implications for PML Risk Stratification

(2010) Leonid Gorelik et al.   ANNALS OF NEUROLOGY

Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy

(2010) Augusto Miravalle et al.   ARCHIVES OF NEUROLOGY

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial

(2010) R. T. Naismith et al.   NEUROLOGY

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial

(2008) Amit Bar-Or et al.   ANNALS OF NEUROLOGY

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE